Integrative molecular profiling of routine clinical prostate cancer specimens. - Wikidata - awgldk - TriplyDB

Integrative molecular profiling of routine clinical prostate cancer specimens.

Integrative molecular profiling of routine clinical prostate cancer specimens.

http://www.wikidata.org/entity/Q35892022

about

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.Translational and clinical implications of the genetic landscape of prostate cancer.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature.Prioritizing precision medicine for prostate cancer A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor

P2860

Q35555483-4BEBD620-1D84-4CDC-B152-440A0BF0D225 Q36004694-1899B3CE-BAC3-41E5-B6B5-0EAFAC5B5F01 Q36131601-C380C14B-3C51-48C9-A166-91CD073D1E60 Q36157852-8BE39D17-C587-44F3-8D72-8F766F031EC9 Q36527826-3CFDA912-BACF-45BF-AAFF-C2FEF508A781 Q37270512-F943E1C9-A8C1-4088-89A7-9264F12E7478 Q38610286-5D1FAFCF-BAD0-4A79-9E7C-F61C74AE35E8 Q38703676-47684AA8-8FF1-4F98-8C68-763A72798C1E Q38982680-167A5EA0-FA04-4D9E-8BFF-935E22625D13 Q39016544-8DA1E0B2-D848-4421-8A53-F4253AB502B6 Q41572452-38CEB27E-DBF4-4392-A2BF-3A2A7B63738C Q49913687-2E5BF9DA-18F4-4ED3-AC58-4B22258A969B Q57693858-B9E38817-02FE-4C47-92D1-55759F6B7D62 Q57809711-19D33701-2EA4-4B35-805C-059EC7A32562

P2860

Integrative molecular profiling of routine clinical prostate cancer specimens.

http://www.wikidata.org/entity/Q35892022

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Integrative molecular profiling of routine clinical prostate cancer specimens.

@ast

Integrative molecular profiling of routine clinical prostate cancer specimens.

@en

type

label

Integrative molecular profiling of routine clinical prostate cancer specimens.

@ast

Integrative molecular profiling of routine clinical prostate cancer specimens.

@en

prefLabel

Integrative molecular profiling of routine clinical prostate cancer specimens.

@ast

Integrative molecular profiling of routine clinical prostate cancer specimens.

@en

P1433

Q35892022-C96753CE-DDA0-4F72-AA70-7BE5E147FA13

P1476

Q35892022-CB48EA38-1A97-44A6-92C3-04E090456CEC

P2093

Q35892022-11DBE7E8-AB3C-4692-A974-5E362FF6E98B

Q35892022-13B5A818-C599-4EBE-A063-A02FCAE96460

Q35892022-1A6B3C0E-4B22-4A23-8384-F65DE4DCA635

Q35892022-5E4665AC-9922-4DBC-BBAE-13B45E7CC644

Q35892022-771CCEBA-CD78-49D5-9E3F-1B499AFC1FBD

Q35892022-7FA39DE5-20FB-430F-89BB-089A2FAADBF6

Q35892022-7FDB744B-0592-44BC-8656-D08FD0A41243

Q35892022-8AB5E685-3671-407A-898E-DE82BB0FC24E

Q35892022-9313B2E4-373E-497D-AB5F-13724F49EE26

Q35892022-97555C24-29EF-46B9-89A0-4FA31B966522

P2860

Q35892022-06EBD8A1-B586-45C8-B1E0-E4C781C04869

Q35892022-0EFF5E67-1F01-458C-AF18-D999BEEDC458

Q35892022-1EF8684E-0B2F-4D3D-9B85-3DA9B9A99EC0

Q35892022-1F8DEBD3-DF3A-46E8-BB05-B42DA08021DC

Q35892022-2C0AF8AF-1FBC-45CB-8DC5-63D93BB2DBC4

Q35892022-2FAB1917-6F29-4217-ACA8-039D495EBEDA

Q35892022-4EA4CBE6-1F26-4E56-A2A0-BFD7DEB18335

Q35892022-4F3B07A5-C469-4B7C-A13E-339319B59AFF

Q35892022-5F8D884A-CFCC-4178-A65F-59817D39751E

Q35892022-77C721EC-2A10-4133-B446-D6CABEF41490

P304

Q35892022-DC2D322C-05E7-47FA-A2EA-8D614D2FA851

P31

Q35892022-0B39BF66-372A-487E-B1B5-1D841EB88881

P356

Q35892022-C2347F0D-25BB-4BA1-93EF-EF024FF2BE00

P433

Q35892022-E6BDBF45-66B9-4CF3-9620-287D5BA3A24E

P478

Q35892022-514F2603-EA07-4C67-A90C-E5EFDF343CA2

P50

Q35892022-29406E06-5C9B-42F8-A59E-8C8C602D904C

Q35892022-ACE4BBE4-46EA-4061-A75C-3CD3C802A694

Q35892022-F2E7B173-114B-4358-A82A-7C53FE843B6A

P577

Q35892022-1C08AD90-36E5-4127-9DFC-7CEC24AA9FF4

P698

Q35892022-29A66814-2892-463A-A3A1-A90F34401D25

P932

Q35892022-C2623E9F-D702-4376-AB3A-4E2289407188

P356

P1433

Annals of Oncology

P1476

Integrative molecular profiling of routine clinical prostate cancer specimens

@en

P2093

A K Cani

http://www.w3.org/2001/XMLSchema#string

A M Amin

http://www.w3.org/2001/XMLSchema#string

A S McDaniel

http://www.w3.org/2001/XMLSchema#string

B L Betz

http://www.w3.org/2001/XMLSchema#string

C S Grasso

http://www.w3.org/2001/XMLSchema#string

C-J Liu

http://www.w3.org/2001/XMLSchema#string

F Y Feng

http://www.w3.org/2001/XMLSchema#string

M J Quist

http://www.w3.org/2001/XMLSchema#string

N J Douville

http://www.w3.org/2001/XMLSchema#string

P S Nelson

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin

Aggressive variants of castration-resistant prostate cancer

Personalized oncology through integrative high-throughput sequencing: a pilot study.

CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets.

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

The androgen/androgen receptor axis in prostate cancer.

P304

1110-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV134

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Kathleen A. Cooney

Daniel H Hovelson

Karen E Knudsen

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25735316

http://www.w3.org/2001/XMLSchema#string

P932

4516047

http://www.w3.org/2001/XMLSchema#string